http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018162974-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f671e91cb8c71df9764cfeccf0a2e1d9 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| filingDate | 2017-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b313fb992772a20225275acd5dd7bb9f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fabee5cda3f83c6ebd57384e33b4263a |
| publicationDate | 2018-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2018162974-A |
| titleOfInvention | Hematopoietic tumor therapeutic agent and screening method |
| abstract | To provide a novel hematopoietic tumor therapeutic agent effective for the treatment of hematopoietic tumor (especially acute leukemia such as AML and ALL), or to provide a screening method for finding the therapeutic agent. Let it be an issue. For the treatment of hematopoietic tumor using, for example, an immune-responsive pathological model animal (eg, pathological model mouse) transplanted with hematopoietic stem cells overexpressing an MLL / AF9 chimeric gene. A screening method characterized by finding an SMS2 inhibitor, a pathological condition characterized by transplanting hematopoietic stem cells overexpressing an MLL / AF9 chimeric gene to an immunoresponsive animal in which the SMS2 gene is knocked out The hematopoietic tumor therapeutic agent characterized by containing a model animal, an SMS2 inhibitor, etc. as an active ingredient can be mentioned. According to the screening method of the present invention, it is possible to find an SMS2 inhibitor capable of enhancing antitumor immune activity and treating hematopoietic tumors. [Selection] Figure 1 |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114717266-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021201170-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021223713-A1 |
| priorityDate | 2017-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 68.